About ImCheck Therapeutics
ImCheck Therapeutics is a company based in Marseille (France) founded in 2015 was acquired by Ipsen in December 2025. It operates as a HealthTech. ImCheck Therapeutics has raised $185.07 million across 6 funding rounds from investors including Pfizer, ARE and EQT. ImCheck Therapeutics offers products and services including ICT01 and ICT41. ImCheck Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Marseille, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImCheck Therapeutics
ImCheck Therapeutics offers a comprehensive portfolio of products and services, including ICT01 and ICT41.
ICT01 is developed for treating Acute Myeloid Leukemia.
ICT41 is designed for immune system modulation therapy.
People of ImCheck Therapeutics
Unlock access to complete
Funding Insights of ImCheck Therapeutics
ImCheck Therapeutics has successfully raised a total of $185.07M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $22.4 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ImCheck Therapeutics
ImCheck Therapeutics has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, ARE and EQT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Earlybird is recognized as a venture capital investor focused on early-stage tech companies.
|
Locked | Locked | Locked | |
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Locked | Locked | Locked | |
|
Biotech startups are funded through venture capital in life sciences.
|
Locked | Locked | Locked |
Investor details for ImCheck Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ImCheck Therapeutics
Investment portfolio details for ImCheck Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImCheck Therapeutics
Detailed financials for ImCheck Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Imcheck Therapeutics Comparisons
Peer comparison for ImCheck Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImCheck Therapeutics
ImCheck Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of ImCheck Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imcheck Therapeutics
Complete news archive for ImCheck Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImCheck Therapeutics
ImCheck Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
ImCheck Therapeutics is headquartered in Marseille, France. It is registered at Marseille, Provence-alpes-cote D'azur, France.
ImCheck Therapeutics is a funded company, having raised a total of $185.07M across 6 funding rounds to date.
ImCheck Therapeutics is engaged in developing next-generation immunotherapeutic antibodies. The company specializes in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. Solutions are targeted for the treatment of cancer, infectious diseases, and autoimmune conditions. Research and development efforts are centered on leveraging unique expertise in immunomodulation to address unmet medical needs across various therapeutic areas.
ImCheck Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
ImCheck Therapeutics offers ICT01 and ICT41.